Company intelligence / Profile preview
Akashi Therapeutics
Cambridge, Massachusetts, United Statesakashirx.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 1
01
Overview
Akashi’s lead candidate HT-100 demonstrated promising anti-fibrotic and muscle-regenerative effects in early-stage trials for Duchenne muscular dystrophy, with favorable safety data at lower doses. However, the program was halted after a serious adverse event at the highest dose cohort; subsequent discussions with the FDA allowed resumption of development at lower doses. Additional candidates include DT‑200 and AT‑300 for DMD.
- Therapeutic areas
- OtherRare Diseases
- Modalities
- Small molecules (HT-100/halofuginone)Selective Androgen Receptor Modulator (SARM; DT-200)Cation channel modulator (AT-300)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaboration with patient advocacy organizations such as CureDuchenneseeking additional investors/development partners
Beyond the preview
Go deeper on Akashi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akashi Therapeutics.